COAST-1: Clinical Knee Osteoarthritis Symptom Treatment 1 Study

COAST-1 is a clinical trial that will assess the efficacy and safety of a drug called AXS-02 (disodium zoledronate tetrahydrate). The drug is administered orally to participants with knee osteoarthritis associated with bone marrow lesions.

The trial is a multicentre, international trial. A total of ~ 346 participants will be enrolled in this study in centres throughout Australia and the United States of America.

Participation in the trial will be approximately 28 weeks and include up to 14 visits to the Menzies Institute for Medical Research. As this is a clinical trial you may or may not benefit directly from participating.

COAST-1 is sponsored by and conducted on behalf of Axsome Therapeutics, Inc

We are looking for patients who:

  • Are aged 50 years or more;
  • Have moderate to severe knee pain on most days;
  • Are able to have a knee MRI scan;
  • May have knee osteoarthritis; and
  • Are interested in volunteering in this study.

More information about this study can be found in our Patient Information Sheet and Consent Form.

If you think you might meet the inclusion criteria and are interested in being involved, please contact the Clinical Trial Coordinator, Kathy Buttigieg (Mon, Tues, Thur & Fri) by

Email; or

Phone; 03 6226 6909